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oxygen supplementation, independently of GA and the du-
ration of respiratory support.  Conclusions: CT-proET-1 is a 
novel promising biomarker for predicting the development 
of BPD in preterm infants when measured at the end of the 
first week of life.  © 2015 S. Karger AG, Basel 
 Introduction 
 Bronchopulmonary dysplasia (BPD) is a common 
complication of premature birth with important long-
term consequences for the increasing number of very 
preterm infants who survive  [1] . Endothelin-1 (ET-1) is 
an endogenous vasoconstrictive peptide, which is in-
volved in the pathogenesis of various lung disorders 
such as pulmonary hypertension, acute respiratory fail-
ure and pulmonary fibrosis  [2] . In preterm newborns, 
raised plasma ET-1 levels have been related to the devel-
opment of respiratory distress syndrome  [3] whereas an 
 Key Words 
 Chronic lung disease · Prematurity · Neonate · Biomarker · 
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 Abstract 
 Background: Bronchopulmonary dysplasia (BPD) is a com-
mon complication in preterm infants. Clinical prediction of 
BPD at an early stage in life is difficult. Plasma proendothe-
lin-1 (CT-proET-1) is a lung injury biomarker in pulmonary 
hypertension and respiratory distress.  Objective: To assess 
the prognostic ability of CT-proET-1 in BPD.  Methods: In 227 
prospectively enrolled preterm infants born at <32 weeks 
gestational age (GA), plasma CT-proET-1 was measured at 
birth, day of life (DOL) 2, 3, 6 and 28, and at 36 weeks post-
menstrual age (PMA). BPD was defined as mild in infants re-
quiring supplemental oxygen at DOL 28 and moderate/se-
vere in those requiring it at 36 weeks PMA.  Results: The pre-
dictive ability of CT-proET-1 for any BPD was poor at birth 
[area under the ROC curve (AUC) 0.654, 95% CI 0.494–0.814], 
moderate at DOL 2 and 3 (AUC 0.769, 95% CI 0.666–0.872) 
and excellent at DOL 6 (AUC 0.918, 95% CI 0.840–0.995). Mul-
tivariable regression analysis revealed that CT-proET-1 levels 
at DOL 2, 3, 6 and 28 were strongly related to the duration of 
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early increase of ET-1 in the tracheal aspirate has been 
shown to correlate with subsequent progression to BPD 
 [4] . In addition, the antiangiogenic effect of ET-1 has 
been linked to the pathogenesis of BPD  [5] and evidence 
from human ex vivo models suggests that ET-1 signal-
ing may play a critical role in the development of a BPD-
like fibrotic process in the immature lung  [6] . Although 
ET-1 is unstable in the peripheral blood and therefore 
less suited for diagnostic use, the more stable C-termi-
nal fragment of the ET-1 precursor (CT-proET-1) can 
be used to estimate ET-1 release  [7] . Our group has re-
cently reported that plasma CT-proET-1 levels at day of 
life (DOL) 3 are strongly correlated with the develop-
ment and severity of respiratory distress syndrome in 
preterm newborns  [8] . However, the prognostic ability 
of ET-1 or CT-proET-1 in relation to BPD remains un-
known.
 Subjects and Methods 
 This study was based on prospectively collected data and blood 
samples from 227 neonates born at a gestational age (GA) of <32 
weeks and cared for at the University Hospitals of Basel and Zu-
rich, Switzerland. A fraction of the participants (n = 121) had been 
enrolled in 2 previous studies aiming to explore plasma CT-pro-
ET-1 levels in neonates in relation to respiratory morbidity at birth 
with measurements at birth and DOL 3 (n = 71, cohort A)  [8] and 
in the context of patent ductus arteriosus with measurements at 
DOL 2 and 6 (n = 50, cohort B)  [9] . The remaining 106 participants 
were newly enrolled and had CT-proET-1 measurements at DOL 
28 and at a postmenstrual age (PMA) of 36 weeks (cohort C, Clin-
ical Trial Registration NCT01644981). The study was approved by 
the institutional review boards of both university hospitals. Writ-
ten informed consent was obtained from the parents prior to en-
rollment.
 A blood volume of 500 μl was collected in EDTA microtubes 
simultaneously with routine blood sampling at different postna-
tal time points (i.e. at birth, DOL 2, 3, 6 and 28, and at 36 weeks 
PMA) depending on the study cohort as was analyzed above. 
Samples were immediately transferred to the central laboratory 
of both study sites for centrifugation and storage at  − 20  °  C until 
analysis. CT-proET-1 levels were measured in batches at the In-
stitute of Clinical Chemistry of the University Hospital Zurich 
using a fully automated immunofluorescent assay (KRYPTOR, 
BRAHMS Biomarkers, Thermo Fisher Scientific, Hennigsdorf, 
Germany). CT-proET-1 assay precision was for repeated serial 
measurements 1.6% at 229.9 pmol/l (intraday, n = 10) and for 
day-to-day measurements 4.1% at 226.3 pmol/l (interday, n = 
10). The laboratory staff was blinded to the aims of the study. 
BPD was defined as mild in infants requiring supplemental oxy-
gen at DOL 28 and moderate/severe in those requiring supple-
mental oxygen at 36 weeks PMA. Since there were no differences 
in CT-proET-1 values at DOL 2 and 3 between cohorts A and B, 
respectively (online suppl. fig.; for all suppl. material, see www.
karger.com/doi/10.1159/000438979), these measurements were 
combined into 1 group (i.e. CT-proET-1 values at DOL 2 and 3). 
Plasma CT-proET-1 levels were compared (Mann-Whitney U 
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 Fig. 1. Circulating CT-proET-1 levels at 
different postnatal time points with respect 
to the severity of BPD. Between-group 
comparisons were performed with the 
Mann-Whitney U test. The number of 
measurements (N) at each time point is 
also noted. Data do not represent longitu-
dinal measurements. Plasma CT-proET-1 
at DOL 2 and 6 derives from 2 separate co-
horts (A and B)  [8, 9] , while values at DOL 
2–3 represent the combination of CT-pro-
ET-1 measurements from these 2 cohorts. 
Circulating CT-proET-1 measurements at 
DOL 28 and at 36 weeks PMA derived from 
a third cohort (C). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
26
/2
01
6 
2:
13
:0
7 
PM
 Proendothelin-1 in BPD  Neonatology 2015;108:293–296 
DOI: 10.1159/000438979
295
test) between infants with and without BPD at birth (umbilical 
cord blood), DOL 2, 3, 6 and 28, and at 36 weeks PMA. Multivari-
able logistic regression models were used to explore the relation 
between CT-proET-1 levels at the above-mentioned time points 
as well as the duration of oxygen dependency (after logarithmic 
transformation).
 Results 
 The characteristics of the three cohorts are presented 
in the online supplementary table. The overall prevalence 
of BPD was 36.6% (n = 83), while 27 infants (11.9%) had 
moderate/severe disease. Circulating CT-proET-1 levels 
at birth and at 36 weeks PMA did not differ between in-
fants with and without BPD ( fig. 1 ). Conversely, plasma 
CT-proET-1 levels at DOL 2, 3, 6 and 28 were significant-
ly higher in infants with BPD compared to non-BPD sub-
jects [median (IQR): 372 (319–409) vs. 258 (192–329) 
pmol/l at DOL 2 and 3, 291 (240–340) vs. 160 (123–210) 
pmol/l at DOL 6 and 210 (169–264) vs. 167 (137–206) 
pmol/l at DOL 28]. No differences were found between 
infants with mild and moderate/severe BPD at any post-
natal time point, but at DOL 6, there was a trend towards 
higher CT-proET-1 values in infants who later developed 
severe/moderate disease. The predictive ability of plasma 
CT-proET-1 was poor at birth [area under the ROC curve 
(AUC) 0.654, 95% CI 0.494–0.814], moderate at DOL 2 
and 3 (AUC 0.769, 95% CI 0.666–0.872) and excellent at 
DOL 6 (AUC 0.918, 95% CI 0.840–0.995). Multivariable 
regression analysis revealed that CT-proET-1 levels at 
DOL 2 3, 6 and 28 were strongly related to the duration 
of oxygen supplementation independent of GA and the 
duration of respiratory support (mechanical ventilation 
and/or nasal continuous positive airway pressure;  ta-
ble 1 ). Interestingly, at DOL 6, the effect of CT-proET-1 
was so strong that it overwhelmed the effect of the other 
confounders.
 Discussion 
 Our findings suggest that CT-proET-1 may be a 
promising biomarker for predicting the development of 
BPD in preterm neonates. This is not surprising, since 
ET-1 signaling has been shown to be involved in the dis-
ruption of molecular pathways that promote alveolar de-
velopment and repair, especially in the immature lung  [6, 
10] . Given our reported time-specific differences in plas-
ma CT-proET-1 levels between neonates who did or did 
not develop BPD, we propose that CT-proET-1 measure-
ments at the end of the first week of life might be of max-
imum diagnostic accuracy. Such an early identification 
of infants at risk of BPD would be of paramount clinical 
importance, because it could allow for the design, imple-
mentation, and evaluation of personalized preventive 
and therapeutic strategies  [11] . The main limitation of 
our study is that it was based on CT-proET-1 measure-
ments which derived in a cross-sectional manner from 3 
independent cohorts and at different postnatal time 
points. Therefore, our findings about the relation be-
tween CT-proET-1 and BPD are suggestive but not con-
clusive. A sufficiently powered prospective trial of serial 
plasma CT-proET-1 measurements is required to further 
evaluate the usefulness of CT-proET-1 in quantifying 
lung injury and predicting progression to BPD in very 
preterm neonates.
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 Table 1.  Predictors of the duration of oxygen dependency
Model: 1 2 3 4  5
R2: 0.431 0.471 0.526 0.447 0.41 1
GA −0.355b −0.313c −0.107 −0.415c −0.285
Days of respiratory
supporta 0.307 0.301c 0.116 0.370c 0.389b
CT-proET-1
Birth 0.154 – – – –
DOL 2 – 0.259b – – –
DOL 6 – – 0.548d – –
DOL 28 – – – 0.226b –
PMA 36 weeks – – – – −0.049
 Multivariable regression model using the log-transformed days 
of oxygen requirement as the dependent variable. Data represent 
adjusted regression β coefficients. 
a Days of mechanical ventilation and/or nasal continuous pos-
itive airway pressure.
b p < 0.05; c p < 0.01; d p < 0.001.
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